Oxford Biomedica (LON:OXB – Get Free Report) issued its earnings results on Wednesday. The biopharmaceutical company reported GBX (30.39) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Oxford Biomedica had a negative return on equity of 48.56% and a negative net margin of 17.85%.
Oxford Biomedica Price Performance
OXB traded down GBX 9 during trading on Wednesday, reaching GBX 484. 5,771,821 shares of the stock were exchanged, compared to its average volume of 1,134,711. The company has a debt-to-equity ratio of 162.16, a current ratio of 2.20 and a quick ratio of 1.67. The company has a market capitalization of £585.87 million, a price-to-earnings ratio of -17.98 and a beta of 1.09. Oxford Biomedica has a 1 year low of GBX 420 and a 1 year high of GBX 952. The business’s 50 day moving average price is GBX 515.68 and its two-hundred day moving average price is GBX 577.12.
Oxford Biomedica News Roundup
Here are the key news stories impacting Oxford Biomedica this week:
- Positive Sentiment: Oxford Biomedica reported 9% first-half revenue growth to £80.2 million and secured a record number of new commercial wins, including 17 new clients. Management maintained its full-year sales outlook, suggesting demand for the company’s cell and gene therapy manufacturing services remains healthy. Oxford Biomedica delivers solid H1 growth, record commercial wins
- Positive Sentiment: The company is advancing a global quality-transformation program using Veeva Quality Cloud. The initiative could improve operational consistency, compliance and scalability as Oxford Biomedica expands its client base. Oxford Biomedica Advances Global Quality Transformation with Veeva Quality Cloud
- Neutral Sentiment: A valuation analysis cited by Yahoo Finance’s earnings preview indicated approximately 35% potential upside based on GF Value. However, this is a model-based estimate rather than a new company catalyst and may carry limited weight while earnings remain negative. Earnings To Watch: Oxford BioMedica PLC
- Negative Sentiment: Quarterly earnings were a loss of GBX30.39 per share, while the company reported a negative 17.85% net margin and negative 48.56% return on equity. Reports also said the first-half loss widened, highlighting pressure on cash generation and the path to profitability. Oxford Biomedica reiterates sales outlook but half-year loss widens
Analysts Set New Price Targets
Check Out Our Latest Research Report on Oxford Biomedica
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.
Read More
- Five stocks we like better than Oxford Biomedica
- Full Throttle: Kratos and GE Fire Up a Next-Gen Defense Engine
- Sandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?
- These 4 Companies Are Monetizing AI Today
- Quantum and Rare Earths? Implications of the Pasqal/USAR Partnership
Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.
